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ABSTRACT 
Background:  Infantile hypertrophic pyloric stenosis (IHPS) is one of the most common 
gastrointestinal obstructions in the infancy requiring surgery.  Reduced-expression of nNOS, 
which plays an important role in the regulation of the human pyloric muscle, is thought to 
underlie IHPS.  The role of nNOS in IHPS has been supported by the genetic association of a 
functional regulatory nNOS polymorphism (−84A>G) with IHPS in Caucasians.  We 
reasoned that the corroboration of this association in a population of different ethnic origin 
would prompt follow-up studies and further investigation of the IHPS pathology at molecular 
level.  Thus, we attempted to reproduce the original findings in a Chinese population of 
comparable size in what would be the first genetic study on IHPS conducted in Chinese.   
Methods:  nNOS −84G>A genotypes were analyzed in 56 patients and 86 controls by 
polymerase chain reaction  and DNA sequencing.  Logistic regression was used to compute 
odds ratios.  
Results:  Our study could not corroborate the association previously reported.  While the 
frequency of the IHPS-associated allele (−84A) in controls (0.205) was similar to that 
reported for Caucasians controls, there was a dramatic difference in −84A frequencies 
between Caucasian and Chinese patients (0.198).  Similarly, there was no difference in the 
nNOS −84G>A genotype distribution between patients and controls.  
Conclusions:  Failure to replicate the initial finding does not detract from its validity, as 
genetic effects may differ across populations.  Differences across populations in linkage 
disequilibrium and/or allele frequencies may contribute to this lack of replication.  The role 
nNOS in IHPS awaits further investigation. 
 




 Infantile hypertrophic pyloric stenosis (IHPS; OMIM179010) is one of the most 
common forms of neonatal gastrointestinal obstruction requiring surgery.  IHPS is 
characterized by the hypertrophy and hyperplasia of the circular muscle layer of the pylorus, 
leading to projectile and persistent vomiting, weight loss and dehydration.1,2  Both open and 
laparoscopic pyloromyotomy are proved to be effective in relieving gastric-outlet blockage.3,4  
The estimated population incidence is 1−5 per 1,000 live births although this is a 
representative value, with a marked preponderance of males to females in a 4:1 ratio.5  
Although the etiology of IHPS is still unclear, genetic predisposition to IHPS is well 
established.  IHPS has been reported to be associated with a variety of chromosomal 
abnormalities, including translocation of chromosome 8 and 17 and a partial trisomy of 
chromosome 9, and a number of inherited syndromes, such as Smith-Lemli-Opitz and 
Cornelia de Lange syndromes.6-8 Approximately 10% of IHPS cases are familial.  Twin 
studies showed a concordance rate of 25-40% in monozygotic twins.  The recurrence risks to 
sibs are around 10% and 2% in males and females, respectively, and the risk of IHPS is 
nearly 17-fold higher in first-degree relatives than the general population.9  
 IHPS is a well-recognized multifactorial trait that results from the interaction between 
genetic and environmental factors.10  Two approaches, linkage and association studies, have 
been widely used to uncover genetic susceptibility to IHPS.  Linkage is based on the analysis 
of the genotypes of members of families that segregates the disease whereas association 
compares the genotypes of affected individuals with those of the general population.  To date, 
five IHPS susceptibility loci have been identified (Table1).  Capon et al.11 analyzed a single 
large multiplex pedigree which included 10 affected individuals, and identified an underlying 
IHPS disease locus in chromosome 16p12-13.  Everett et al.12 using a SNP-based high-
density linkage analysis in a cohort of 81 IHPS pedigrees, uncovered two IHPS disease loci 
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that mapped to chromosome 11q14-q22 and Xq23 respectively.  In an extended IHPS family 
including 8 affected individuals, chromosome 16q24 was found to be linked with the disease. 
13 The chromosome 12q24.2-q24.31 region, where the gene encoding the neuronal nitric 
oxide synthase (nNOS) maps, was found to be implicated in IHPS14 through a linkage 
analysis conducted in 1996.  However, it was not until 2004 that an association study taking 
nNOS as a candidate gene was carried out.  
 nNOS is a key enzyme in the synthesis of the nitric oxide (NO), which plays an 
important role in the relaxation of the pyloric smooth muscle.15  There is a growing body of 
evidence indicating that reduced expression of nNOS is a common hallmark of IHPS.16-18  It 
has been shown that the administration of exogenous NO donor to sphincter tissues with low 
NOS expression can restore the capacity of relaxation,19 indicating that the reduced-
expression of nNOS may act as a mechanism for the defective relaxation of pyloric muscle 
and formation of pyloric mass, thought to be responsible for the obstruction of upper 
alimentary tract.  Moreover, animal studies in mice have shown that absence of nNOS gene 
causes a phenotype closely resembling that of human IHPS patients.20,21  The nNOS gene, 
which can generate nine distinct first-exon transcripts (exon 1a-1i) in human gut by 
alternative promoter usage, is one of the most structurally diverse human genes identified22-24 
in terms of first-exon usage and complexity of expression patterns, which suggests the 
existence of a temporospatial regulation of its expression under different physiological or 
pathological conditions.  
Recently, Saur et al.25 found significantly decreased expression of total nNOS mRNA 
in pyloric tissues of IHPS patients when compared to that of normal controls.  Furthermore, a 
SNP at nucleotide −84 (G>A, rs41279104) in the nNOS exon 1c proximal promoter seemed 
to account for the decreased expression observed.  Cell lines carrying the −84AA genotype 
showed a 30% decreased nNOS expression and significant attenuation of NO/cGMP signal 
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pathway when compared with those carrying the −84GG genotype.25  This functional SNP 
was also shown to be associated with IHPS in a relatively small case-control study, including 
16 patients and 81 controls in a Caucasian population.  
 In view of the role played by nNOS in IHPS development we opted to pursue further 
investigation.  We reasoned that the evaluation of the nNOS association in a population of 
different ethnic origin from that of the initial finding would definitively increase confidence 
in the finding and prompt follow-up studies and further investigation of the pathology 
underlying IHPS at molecular level.  Thus, we attempted to reproduce the initial association 
found in Caucasians in a Chinese population in what is the first genetic study on IHPS ever 
conducted in Chinese population.   
 
MATERIALS AND METHODS 
Patients and control samples 
 This study consisted of fifty-six incident patients (46 male and 10 female) with 
sporadic IHPS treated with pyloromyotomy, and eighty-six healthy unrelated Han Chinese 
(70 male and 16 female) as controls.  All patients were consecutively recruited from January 
2003 to January 2009 at Shenzhen Children’s Hospital.  Normal controls without any 
congenital diseases were unselected subjects from the same region during the same period.  
This study was approved by the Ethics Committee of Shenzhen Children’s Hospital and the 
institutional review board of the University of Hong Kong.  At recruitment, written informed 
consent was obtained from all participating individuals. 
 
DNA sequence analyses 
 DNA was extracted from peripheral blood using a QIAamp-Blood kit (Qiagen).  All 
patients and controls were genotyped using PCR and direct sequencing.  Around 10% random 
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samples were tested twice and the results were concordant for all of the masked duplicate sets.  
The PCR primers for amplification of the nNOS regulatory region containing −84 G>A were 
5’- AAA GGT CAG AGC CTG GGA AG (forward) and 5’- ACC CCC TCT CAG ACA 
GTG C (reverse), which generate a 304-bp fragment and the forward primer was used for 
sequencing.  Amplification of this DNA fragment was accomplished under the following 
conditions: the 25-μl reaction mixture consisted of ~100 ng template DNA, 0.5 µM each 
primer, 0.2 mM dNTP, 2.0 mM MgCl2, and 1.0 unit of Taq DNA polymerase (Applied 
Biosystems, Foster City, CA).  The reaction was carried out in the following conditions: an 
initial melting step of 5 min at 95 oC, followed by 35 cycles of 30 s at 94 oC, 30 s at 58 oC, 
and 45 s at 72 oC, and a final elongation step of 7 min at 72 oC.  PCR products were 
sequenced using an ABI PRISM® Big DyeTM Terminator v 3.1 Cycle sequencing kit (Applied 
Biosystems, Foster City, CA) and an ABI 3730 automated sequencer (Applied Biosystems, 
Foster City, CA).  
 
Statistical analysis 
 The association between the polymorphism and risk of IHPS was estimated by odds 
ratios (ORs) and their 95% confidence intervals (CIs), which were calculated by 




 In this study, we examined a total of 56 sporadic Chinese IHPS patients and 86 
ethnically and gender matched controls by direct sequencing the G>84A polymorphism in the 
regulatory region of nNOS.  Table 2 shows allele frequencies and genotype distributions of 
nNOS in cases and controls.  The allele frequencies for nNOS −84A allele were 0.205 in cases 
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and 0.198 in controls, thus no significantly different (p = 0.875).  Among controls, the 
genotype distribution was in Hardy-Weinberg equilibrium (p = 0.265), supporting the 
correctness of our genotyping procedure.  Also, there was not differences in the genotype 
distribution of nNOS −84G>A between cases and controls.  The frequencies of nNOS −84GG 
and GA genotypes in cases were similar to those in controls (66.1% and 26.8% versus 66.3% 
and s27.9%, p = 0.922), and the same was true with the frequencies of rare homozygous AA 
genotype (7.1% in patients versus 5.8% in controls, p = 0.766).  We also used unconditional 
logistic regression model to estimate the association between the genotypes and risk of IHPS.  
The results show there were no association between the genotypes of G−84A site at the nNOS 
gene and risk of IHPS, even when the GA and AA genotypes were combined (OR:1.01; 95% 
CI = 0.47-2.19). 
 
DISCUSSION  
 Numerous studies have been conducted to quest for IHPS susceptibility loci,11-14,25 but 
thus far, apart from the reported association of the condition with nNOS in the Caucasian 
population, no other causal gene has been identified.  We reasoned that the evaluation of the 
nNOS association in a population of different ethnic origin would definitively increase 
confidence in the finding and prompt follow-up studies and further investigation of the 
pathology underlying IHPS at molecular level.  Nevertheless, we failed to replicate the initial 
nNOS-IHPS association.   
 Failure to replicate the initial finding in a different population does not detract from 
its validity, since there is genuine diversity of the genetic effects in different populations as 
exemplified by the studies26,27 linking cancer to a polymorphism in the CASP8 promoter.  
The CASP8 SNP was shown to be associated with susceptibility to multiple cancers in 
Chinese but not in Caucasians.   
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 Lack of replication of an association in a different population may also be due to the 
following related scenarios: a) linkage disequilibrium (LD) differences across populations; b) 
large differences in allele frequencies in which case, some true associations may not be 
replicated, regardless of the sample size of the study; c) false positives in the original claims.   
 We looked into each of these scenarios.  If failure to replicate was due to differential 
linkage disequilibrium, that would mean that the marker under scrutiny is not causal and it 
cannot be used as a prognostic/diagnostic test across different populations.  Using HapMap 
phase III data, we investigated the LD in the nNOS region in both Caucasians and Chinese.  
LD is quite similar in both populations (data not shown), as are the frequencies of the IHPS-
associated allele in Caucasian and Chinese controls (0.173 and 0.198 respectively).  Even if 
the frequency of −84G>A of differed across populations, the biological impact on the risk to 
disease would be consistent28, and the only reason preventing the replication of the 
association of this variant with modest effect with IHPS, would be the sample size studied.  
Therefore, we believe that scenarios a) and b) can be ruled out as the reasons behind the 
discrepancy across populations regarding the association of the nNOS polymorphism with 
IHPS.  Many gene–disease associations proposed to date have not been consistently 
replicated across different populations, and this reflected false positives in the original claims 
in many cases.  
 We acknowledge that the study presented here has limitations, namely small sample 
size, a problem inherent to low incidence complex diseases.  Yet, as stated above, we believe 
that increasing the sample size would not have changed our results;  after all, the sample sizes 
are comparable. Interestingly, the original association described by Saur et al.25 could not be 
replicated by Chung et al group even in  a similar study conducted on Caucasian 
individuals.29  Indeed, the role of nNOS in IHPS awaits further investigation.  
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 Recent advances indicated that a complex system, including pyloric smooth muscle, 
the interstitial cells of Cajal, gastrointestinal hormones and enteric nervous system, may be 
involved in the development of IHPS29 . Given the high number of genes involved in these 
pathways, it is reasonable to hypothesize that IHPS may be caused by polymorphisms or 
mutations occurring in different genes.  Therefore, it would be necessary to systematically 
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Table 1:  Genetic Studies on IHPS 
References Type Ethnicity Sample size IHPS susceptibility loci 
Chung, et al. [14] Linkage analysis Caucasian 27 families (229 individuals; 87 
with IHPS)  
NOS1 (12q12.2-q24.31)  
Capon, et al. [11] Linkage analysis Caucasian 3-generation family (10 affected)    16p13-p12 
Everett, et al. [12] Linkage analysis Caucasian 81 families (302 individuals; 206 
with IHPS)  
11q14-q22 and Xq23i 
Everett, et al. [13] Linkage analysis Caucasian 1 family, (8  with IHPS)   16q24  
Saur, et al. [25] Association study Caucasian Case-control; 16 IHPS and 81 
controls  
−84 (G>A) of nNOS has been identified 







Table 2:  nNOS −84 G >A genotypes in cases and controls and their association with IHPS 
     Genotypes 
Cases (n=56) Controls (n=86) 
OR (95%CI) 
 Number  (%)   Number  (%) 
GG 37    (66.1) 57    (66.3) 1.00 
GA 15     (26.8) 24    (27.9) 0.96 (0.42-2.21) 
AA 4      (7.1)  5     (5.8) 1.23 (0.26-5.77) 
GA+AA 19     (33.9)        29   (33.7) 1.01(0.47-2.19) 
A allele 0.205 0.198 P = 0.875 
 
 
